Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Calliditas Therapeutics AB - American Depositary Shares (NQ:CALT)

40.00 UNCHANGED
Last Price Updated: 3:53 PM EDT, Sep 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Calliditas Therapeutics AB - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
The company previously had an accelerated approval for its IgA nephropathy treatment. 
Via Investor's Business Daily
CALT Stock Earnings: Calliditas Therapeutics Misses EPS, Beats Revenue for Q2 2024
CALT stock results show that Calliditas Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BALY, MRO, SHCR, CALT on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
Week In Review: MediLink And BioNTech Form $1.8 Billion ADC Partnership
Suzhou MediLink partnered with Germany’s BioNTech to use MediLink’s TMALIN antibody-drug conjugate platform. MediLink will receive an upfront payment of $25 million and up to $1.8 billion in... 
Via Talk Markets
Critical Insights From Calliditas Therapeutics Analyst Ratings: What You Need To Know
 
Via Benzinga
Crude Oil Rises Sharply; Elbit Systems Shares Fall After Q1 Results
 
Via Benzinga
Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Asahi Kasei Makes $1.1B Offer For Swedish Drugmaker Calliditas Therapeutics, Enhancing Pharma Growth Strategy
Asahi Kasei's $1.1 billion acquisition of Calliditas Therapeutics offers 208 SEK per share in cash. The deal boosts Asahi Kasei's global presence in immunology and renal disease markets, aligning with... 
Via Benzinga
Dow Dips Over 100 Points; GameStop Shares Spike higher
 
Via Benzinga
Topics Stocks
Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why GameStop Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are a hot topic as investors return to trading on Tuesday following the long holiday weekend! 
Via InvestorPlace
Apple To Rally Over 47%? Here Are 10 Top Analyst Forecasts For Friday
 
Via Benzinga
CALT Stock Earnings: Calliditas Therapeutics Misses EPS, Misses Revenue for Q1 2024
CALT stock results show that Calliditas Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
 
Via Benzinga
Palo Alto Networks Issues Weak Outlook, Joins Teladoc Health, SolarEdge Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures trading lower by around 70 points on Wednesday. 
Via Benzinga
Topics Stocks
What's Going On With Vera Therapeutics Stock Today?
Vera Therapeutics' significant market movements! Discover the latest on atacicept in IgA nephropathy trials, analyst ratings, and FDA approvals. 
Via Benzinga
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of DouYu International Holdings Limited (NASDAQ: DOYU) rose sharply during Thursday’s session after announcing a share repurchase program. 
Via Benzinga
NeoGenomics, Energy Fuels And Other Big Stocks Moving Lower On Thursday
U.S. stocks traded higher, with the Dow Jones index gaining around 80 points on Thursday. Shares of NeoGenomics, Inc. (NASDAQ: NEO) shares fell sharply during Thursday’s session after Natera won a... 
Via Benzinga
Topics Intellectual Property Lawsuit Stocks
Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. 
Via Benzinga
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
Via Benzinga
Micron Posts Upbeat Sales, Joins Calliditas Therapeutics And Other Big Stocks Moving Higher In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow Jones futures gaining more than 150 points on Thursday. 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Why Shares of Calliditas Therapeutics Are Rising Thursday
The company's shares rose in response to a competitors' mixed phase 3 trial. 
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.